Form 4: Ligand Pharmaceuticals Director Jason Haas Reports Significant Equity Grant

Ligand Pharmaceuticals Inc. Director Jason Haas has reported the acquisition of 1,209 restricted stock units and 5,783 non-qualified stock options, granted by the Board of Directors on June 6, 2025.

Summary

• Jason Haas, a Director of Ligand Pharmaceuticals Inc. (LGND), received equity grants on June 6, 2025, as reported in a Form 4 filing.
• The grants include 1,209 restricted stock units (RSUs) and 5,783 non-qualified stock options.
• Each RSU represents a contingent right to receive one share of the Issuer's common stock, acquired at a price of $0.0.
• The non-qualified stock options have an exercise price of $105.99 per share and are set to expire on June 6, 2035.
• Both the RSUs and options fully vest on the earlier of the date of the next annual meeting of the Company stockholders following the grant date or the first anniversary of the grant date (June 6, 2025).
• Following these transactions, Jason Haas beneficially owns 6,606 shares of common stock directly and 5,783 non-qualified stock options directly.

Sentiment

Score: 7

Explanation: The sentiment is positive as the equity grant aligns the director's interests with shareholder value, indicating confidence and commitment. However, as a routine compensation disclosure, it has a limited direct impact on immediate market sentiment.

Positives

• Director Jason Haas received a significant equity grant, which aligns his financial interests with those of the company's shareholders.
• The grant includes both restricted stock units and stock options, providing a balanced mix of immediate and long-term incentives for the director.
• The specified vesting schedule encourages long-term commitment and performance from the director.

Future Outlook

The vesting schedule for the granted equity, tied to the next annual meeting or the first anniversary of the grant, indicates a future alignment of the director's interests with long-term shareholder value, incentivizing sustained performance.

Industry Context

This filing is a standard disclosure of insider equity compensation and does not provide specific insights into broader industry trends or competitive dynamics, beyond reflecting common practices of aligning executive and director incentives with company performance through equity grants.

Comparison to Industry Standards

• This Form 4 filing details an individual director's equity compensation and does not provide sufficient information for a direct comparison to industry-wide compensation benchmarks or specific project results of comparable companies.

Related Party Transactions

• The equity grant to Director Jason Haas is a standard form of compensation and aligns with typical corporate governance practices for director remuneration, designed to align management incentives with shareholder interests.

Stakeholder Impact

• Shareholders: The equity grant to Director Jason Haas is intended to further align his interests with those of the shareholders, potentially leading to decisions that enhance long-term shareholder value.
• Employees: No direct impact on general employees is indicated by this specific filing.

Next Steps

• Vesting of the 1,209 Restricted Stock Units and 5,783 Non-Qualified Stock Options will occur on the earlier of the next annual meeting of stockholders or June 6, 2026.
• Potential exercise of the non-qualified stock options by Jason Haas after they vest and before their expiration date of June 6, 2035.

Key Dates

Keywords

Ligand Pharmaceuticals, LGND, SEC Form 4, Insider Transaction, Equity Grant, Restricted Stock Units, Stock Options, Director Compensation